Resverlogix expands cardiovascular disease franchise to NexVas VI

By Elaine Rigoli

Tampa, Fla., Aug. 14 - Resverlogix Corp. has expanded its cardiovascular disease research efforts focused on vascular inflammation and said preliminary findings demonstrated that NexVas compounds have inhibitory effects on a number of inflammation markers comparable to and better than its positive control, a chemical entity representative of Atherogenics, Inc's vascular inflammatory drug (AGI-1067) currently in pivotal phase 3 clinical studies.

"Currently, our compounds are early in development and have not yet surpassed the AGI-1067 control in potency. However, having successfully increased the potency of our NexVas PR compounds, we are confident in our ability to improve potency with ongoing chemistry efforts and mining of our patent estate," president and chief executive officer Donald J. McCaffrey said in a company news release.

In 1998, the American Heart Association established a special advisory board panel to identify novel targets for cardiovascular disease risk. One of the key findings from this panel was that markers of inflammation were one class of emerging targets.

Resverlogix said this research expansion will continue to position the company as a leader in cardiovascular disease while presenting multiple commercial opportunities.

Resverlogix is a biotechnology company based in Calgary, Alta.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.